#BEGIN_DRUGCARD DB00414

# AHFS_Codes:
Not Available

# ATC_Codes:
A10BB31

# Absorption:
Rapidly absorbed from the GI tract.

# Biotransformation:
Extensively metabolized in the liver to the active metabolite hydroxyhexamide, which exhibits greater hypoglycemic potency than acetohexamide. Hydroxyhexamide is believed to be responsible for prolonged hypoglycemic effects.

# Brand_Mixtures:
Not Available

# Brand_Names:
Cyclamide
Dimelin
Dimelor
Dymelor
Gamadiabet
Hypoglicil
Metaglucina
Minoral
Ordimel
Tsiklamid

# CAS_Registry_Number:
968-81-0

# ChEBI_ID:
28052

# Chemical_Formula:
C15H20N2O4S

# Chemical_IUPAC_Name:
1-[(4-acetylbenzene)sulfonyl]-3-cyclohexylurea

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
15598

# Description:
A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Hypoglycemic Agents
Sulfonylureas

# Drug_Interactions:
Acebutolol	Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia.
Acetylsalicylic acid	Acetylsalicylic acid increases the effect of sulfonylurea, acetohexamide.
Atenolol	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
Betaxolol	The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia.
Bisoprolol	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
Carteolol	The beta-blocker, carteolol, may decrease symptoms of hypoglycemia.
Carvedilol	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
Chloramphenicol	Chloramphenicol may increase the effect of sulfonylurea, acetohexamide.
Clofibrate	Clofibrate may increase the effect of sulfonylurea, acetohexamide.
Dicumarol	Dicumarol may increase the effect of sulfonylurea, acetohexamide.
Esmolol	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
Labetalol	The beta-blocker, labetalol, may decrease symptoms of hypoglycemia.
Metoprolol	The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.
Nadolol	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
Oxprenolol	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
Phenylbutazone	Phenylbutazone may increase the effect of acetohexamide.
Pindolol	The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
Practolol	The beta-blocker, practolol, may decrease symptoms of hypoglycemia.
Propranolol	The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
Rifampin	Rifampin may decrease the effect of sulfonylurea, acetohexamide.
Sotalol	The beta-blocker, sotalol, may decrease symptoms of hypoglycemia.
Timolol	The beta-blocker, timolol, may decrease symptoms of hypoglycemia.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
2.44

# Experimental_Logs:
-2.06

# Experimental_Water_Solubility:
3430 mg/L (at 37 °C)

# Food_Interactions:
Avoid alcohol.
Take without regard to meals.

# GenBank_ID:
Not Available

# Generic_Name:
Acetohexamide

# HET_ID:
Not Available

# Half_Life:
Elimination half-life of the parent compound is 1.3 hours and the elimination half-life of the active metabolite is approximately 5-6 hours.

# InChI_Identifier:
InChI=1S/C15H20N2O4S/c1-11(18)12-7-9-14(10-8-12)22(20,21)17-15(19)16-13-5-3-2-4-6-13/h7-10,13H,2-6H2,1H3,(H2,16,17,19)

# InChI_Key:
InChIKey=VGZSUPCWNCWDAN-UHFFFAOYSA-N

# Indication:
Used in the management of diabetes mellitus type 2 (adult-onset).

# KEGG_Compound_ID:
C06806

# KEGG_Drug_ID:
D00219

# LIMS_Drug_ID:
414

# Mechanism_Of_Action:
Sulfonylureas such as acetohexamide bind to an ATP-dependent K<sup>+</sup> channel on the cell membrane of pancreatic beta cells. This inhibits a tonic, hyperpolarizing outflux of potassium, which causes the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca<sup>2+</sup> channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.

# Melting_Point:
188-190 °C

# Molecular_Weight_Avg:
324.395

# Molecular_Weight_Mono:
324.114377828

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164777011

# Pharmacology:
Acetohexamide is an intermediate-acting, first-generation oral sulfonylurea. It lowers blood sugar by stimulating the pancreatic beta cells to secrete insulin and by helping the body use insulin efficiently. The pancreas must produce insulin for this medication to work. Acetohexamide has one-third the potency of chlorpropamide, and twice the potency of tolbutamide; however, similar hypoglycemic efficacy occurs with equipotent dosage of sulfonylureas.

# Predicted_LogP_Hydrophobicity:
1.72

# Predicted_LogS:
-3.8

# Predicted_Water_Solubility:
4.83e-02 g/l

# Primary_Accession_No:
DB00414

# Protein_Binding:
90%

# PubChem_Compound_ID:
1989

# PubChem_Substance_ID:
46505821

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00773

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Acetohexamid

# Synthesis_Reference:
Not Available

# Toxicity:
Oral, rat LD<sub>50</sub>: 5 gm/kg; Oral, mouse LD<sub>50</sub>: >2500 mg/kg. Symptoms of an acetohexamide overdose include hunger, nausea, anxiety, cold sweats, weakness, drowsiness, unconsciousness, and coma.

# Update_Date:
2013-02-08 16:19:19 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Acetohexamide

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CBR1

# Phase_1_Metabolizing_Enzyme_1_ID:
5251

# Phase_1_Metabolizing_Enzyme_1_Name:
Carbonyl reductase [NADPH] 1

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Carbonyl reductase [NADPH] 1
MSSGIHVALVTGGNKGIGLAIVRDLCRLFSGDVVLTARDVTRGQAAVQQLQAEGLSPRFH
QLDIDDLQSIRALRDFLRKEYGGLDVLVNNAGIAFKVADPTPFHIQAEVTMKTNFFGTRD
VCTELLPLIKPQGRVVNVSSIMSVRALKSCSPELQQKFRSETITEEELVGLMNKFVEDTK
KGVHQKEGWPSSAYGVTKIGVTVLSRIHARKLSEQRKGDKILLNACCPGWVRTDMAGPKA
TKSPEEGAETPVYLALLPPDAEGPHGQFVSEKRVEQW

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P16152

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
KCNJ1

# Drug_Target_1_GenBank_ID_Gene:
U12541

# Drug_Target_1_GenBank_ID_Protein:
529313

# Drug_Target_1_GeneCard_ID:
KCNJ1

# Drug_Target_1_Gene_Name:
KCNJ1

# Drug_Target_1_Gene_Sequence:
>1176 bp
ATGAATGCTTCCAGTCGGAATGTGTTTGACACGTTGATCAGGGTGTTGACAGAAAGTATG
TTCAAACATCTTCGGAAATGGGTCGTCACTCGCTTTTTTGGGCATTCTCGGCAAAGAGCA
AGGCTAGTCTCCAAAGATGGAAGGTGCAACATAGAATTTGGCAATGTGGAGGCACAGTCA
AGGTTTATATTCTTTGTGGACATCTGGACAACGGTACTTGACCTCAAGTGGAGATACAAA
ATGACCATTTTCATCACAGCCTTCTTGGGGAGTTGGTTTTTCTTTGGTCTCCTGTGGTAT
GCAGTAGCGTACATTCACAAAGACCTCCCGGAATTCCATCCTTCTGCCAATCACACTCCC
TGTGTGGAGAATATTAATGGCTTGACCTCAGCTTTTCTGTTTTCTCTGGAGACTCAAGTG
ACCATTGGATATGGATTCAGGTGTGTGACAGAACAGTGTGCCACTGCCATTTTTCTGCTT
ATCTTTCAGTCTATACTTGGAGTTATAATCAATTCTTTCATGTGTGGGGCCATCTTAGCC
AAGATCTCCAGGCCCAAAAAACGTGCCAAGACCATTACGTTCAGCAAGAACGCAGTGATC
AGCAAACGGGGAGGGAAGCTTTGCCTCCTAATCCGAGTGGCTAATCTCAGGAAGAGCCTT
CTTATTGGCAGTCACATTTATGGAAAGCTTCTGAAGACCACAGTCACTCCTGAAGGAGAG
ACCATTATTTTGGACCAGATCAATATCAACTTTGTAGTTGACGCTGGGAATGAAAATTTA
TTCTTCATCTCCCCATTGACAATTTACCATGTCATTGATCACAACAGCCCTTTCTTCCAC
ATGGCAGCGGAGACCCTTCTCCAGCAGGACTTTGAATTAGTGGTGTTTTTAGATGGCACA
GTGGAGTCCACCAGTGCTACCTGCCAAGTCCGGACATCCTATGTCCCAGAGGAGGTGCTT
TGGGGCTACCGTTTTGCTCCCATAGTATCCAAGACAAAGGAAGGGAAATACCGAGTGGAT
TTCCATAACTTTAGCAAGACAGTGGAAGTGGAGACCCCTCACTGTGCCATGTGCCTTTAT
AATGAGAAAGATGTTAGAGCCAGGATGAAGAGAGGCTATGACAACCCCAACTTCATCTTG
TCAGAAGTCAATGAAACAGATGACACCAAAATGTAA

# Drug_Target_1_General_Function:
Involved in inward rectifier potassium channel activity

# Drug_Target_1_General_References:
7635463	Krishnan SN, Desai T, Ward DC, Haddad GG: Isolation and chromosomal localization of a human ATP-regulated potassium channel. Hum Genet. 1995 Aug;96(2):155-60.
7929082	Shuck ME, Bock JH, Benjamin CW, Tsai TD, Lee KS, Slightom JL, Bienkowski MJ: Cloning and characterization of multiple forms of the human kidney ROM-K potassium channel. J Biol Chem. 1994 Sep 30;269(39):24261-70.
8190102	Yano H, Philipson LH, Kugler JL, Tokuyama Y, Davis EM, Le Beau MM, Nelson DJ, Bell GI, Takeda J: Alternative splicing of human inwardly rectifying K+ channel ROMK1 mRNA. Mol Pharmacol. 1994 May;45(5):854-60.
9002665	Mutations in the gene encoding the inwardly-rectifying renal potassium channel, ROMK, cause the antenatal variant of Bartter syndrome: evidence for genetic heterogeneity. International Collaborative Study Group for Bartter-like Syndromes. Hum Mol Genet. 1997 Jan;6(1):17-26.

# Drug_Target_1_HGNC_ID:
HGNC:6255

# Drug_Target_1_HPRD_ID:
08981

# Drug_Target_1_ID:
709

# Drug_Target_1_Locus:
11q24

# Drug_Target_1_Molecular_Weight:
44795

# Drug_Target_1_Name:
ATP-sensitive inward rectifier potassium channel 1

# Drug_Target_1_Number_of_Residues:
391

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01007	IRK

# Drug_Target_1_Protein_Sequence:
>ATP-sensitive inward rectifier potassium channel 1
MNASSRNVFDTLIRVLTESMFKHLRKWVVTRFFGHSRQRARLVSKDGRCNIEFGNVEAQS
RFIFFVDIWTTVLDLKWRYKMTIFITAFLGSWFFFGLLWYAVAYIHKDLPEFHPSANHTP
CVENINGLTSAFLFSLETQVTIGYGFRCVTEQCATAIFLLIFQSILGVIINSFMCGAILA
KISRPKKRAKTITFSKNAVISKRGGKLCLLIRVANLRKSLLIGSHIYGKLLKTTVTPEGE
TIILDQININFVVDAGNENLFFISPLTIYHVIDHNSPFFHMAAETLLQQDFELVVFLDGT
VESTSATCQVRTSYVPEEVLWGYRFAPIVSKTKEGKYRVDFHNFSKTVEVETPHCAMCLY
NEKDVRARMKRGYDNPNFILSEVNETDDTKM

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
In the kidney, probably plays a major role in potassium homeostasis. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. This channel is activated by internal ATP and can be blocked by external barium

# Drug_Target_1_SwissProt_ID:
P48048

# Drug_Target_1_SwissProt_Name:
IRK1_HUMAN

# Drug_Target_1_Synonyms:
ATP-regulated potassium channel ROM-K
Kir1.1
Potassium channel, inwardly rectifying subfamily J member 1

# Drug_Target_1_Theoretical_pI:
9.04

# Drug_Target_1_Transmembrane_Regions:
78-102
156-177

#END_DRUGCARD DB00414
